ADJUVANT CHEMOTHERAPY IN GASTRIC CANCER QUITO-ECUADOR

Ivonne Bravo Galarza; Christian Aguilar Erazo; Ana Calderon Cervantes; Mabel Sisalima Vazquez; Nelson Urbina Moreno; Priscila Yepez Guachamin; Alex Montes de Oca Gavilanez; Maria Herrera Herrera

Volume : VIII, Issue : IX, September - 2019

ADJUVANT CHEMOTHERAPY IN GASTRIC CANCER QUITO-ECUADOR

Ivonne Bravo Galarza, Christian Aguilar Erazo, Ana Calderon Cervantes, Mabel Sisalima Vazquez, Nelson Urbina Moreno, Priscila Yepez Guachamin, Alex Montes De Oca Gavilanez, Maria Herrera Herrera

Abstract :

OBJECTIVE: To determine the overall survival time in patients treated with adjuvant chemoradiotherapy. METHODS: Retrospective study of patients with a diagnosis of gastric adenocarcinoma or gastroesophageal junction who received adjuvant chemoradiotherapy treatment during the years 2011 to 2015. RESULTS: We analized 197 subjects of which 115 were men (58.4%) and 82 women (41.6%) were included in the analysis; between the ages of 18 and 89 years old, distributed in clinical stages IB to IIIC, showing a general average survival of 51.5 months with a Log Rank of 2.98; 95% CI (45.7 - 57.4) with a general survival of up to 90 months. CONCLUSION: The study showed a greater overall survival than the data reported in the Intergroup 0116 and ARTIST study.